Market Overview:
The global familial amyloid polyneuropathy market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of FAP, rising awareness about FAP, and growing demand for better treatment options for FAP patients. Based on type, the global familial amyloid polyneuropathy market is segmented into FAP-I, FAP-II, FAP-III, andF AP-IV. TheF AP-I segment is expected to account for the largest share of the global familial amyloid polyneuropathy market in 2018.
Product Definition:
Familial amyloid polyneuropathy (FAP) is a rare, inherited disorder that causes nerve damage in the hands and feet. FAP is caused by the abnormal build-up of a protein called amyloid in the nerves. Amyloid is made up of small proteins called peptides. These peptides can clump together to form long, sticky strands called fibrils. The fibrils can damage nearby cells and tissues. FAP affects both men and women equally and usually appears between the ages of 30 and 50 years old. Symptoms include numbness or tingling in the hands or feet, difficulty walking, weakness in the arms or legs, pain, constipation, heart problems, and vision loss.
FAP-I:
Familial Amyloid Polyneuropathy (FAP) is a rare neurodegenerative disorder affecting the peripheral nervous system. It is an autosomal dominant genetic disorder with an estimated incidence of 1 per 100,000 individuals. The disease may remain asymptomatic during its early stages.
FAP-II:
Familial Amyloid Polyneuropathy (FAP) is a rare neurodegenerative disorder affecting the peripheral nervous system. It is an autosomal dominant genetic disorder with an average prevalence rate of 1 per 100,000 individuals. The disease has a wide range of clinical presentations that may include asymptomatic or minimally symptomatic to severe and fatal forms.
Application Insights:
Based on application, the market is segmented into hospitals and clinics, other applications including home care settings and pharmacies, and regional centers. Hospitals and clinics accounted for the largest share in 2017 owing to availability of advanced healthcare facilities at a global level coupled with increasing prevalence of diabetes-related complications.
Familial amyloid polyneuropathy affects mostly patients aged 60 years or above. To reduce this demographic impact, manufacturers are developing drugs specifically designed for use in elderly population group (above 65 years). For instance, Sun Pharmaceutical Industries Ltd., developed ¢â‚¬Å“Alzheimer¢â‚¬ drug candidate which targets Amyloid-ß (Aß) plaques using familial amyloid polyneuropathy as a disease mechanism. The company has received Orphan Designation from European Commission for its lead compound development program under this initiative.
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare facilities and favorable reimbursement policies are some of the major factors responsible for its growth. In addition, increasing prevalence of neurodegenerative diseases, rising awareness about available treatment options, and availability of effective therapies are also expected to drive regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative CAGR during the forecast period owing to growing medical tourism in emerging economies such as India and China. In addition, an increase in healthcare expenditure by governments along with rise in disposable income is further expected to boost this market over the next eight years.
Growth Factors:
- Increasing incidence of Familial Amyloid Polyneuropathy (FAP) due to growing awareness about the disease and its symptoms.
- Growing number of research studies on Familial Amyloid Polyneuropathy (FAP), which is expected to result in better diagnosis and treatment options for the patients.
- increasing prevalence of diabetes and obesity, which are known risk factors for developing Familial Amyloid Polyneuropathy (FAP).
- rising demand for novel therapeutics for treating Familial Amyloid Polyneuropathy (FAP), especially from emerging markets such as China and India .
- increasing focus on rare diseases such as Familial Amyloid Polyneuropathy (FAP), which is expected to spur investments in R&D activities related to this indication
Scope Of The Report
Report Attributes
Report Details
Report Title
Familial Amyloid Polyneuropathy Market Research Report
By Type
FAP-I, FAP-II, FAP-III, FAP-IV
By Application
Hospitals and Clinics, Others
By Companies
Pfizer, GSK, Ionis, Alnylam, Corino Therapeutics, Proclara Bioscience, Arcturus Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
214
Number of Tables & Figures
150
Customization Available
Yes, the report can be customized as per your need.
Global Familial Amyloid Polyneuropathy Market Report Segments:
The global Familial Amyloid Polyneuropathy market is segmented on the basis of:
Types
FAP-I, FAP-II, FAP-III, FAP-IV
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals and Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- GSK
- Ionis
- Alnylam
- Corino Therapeutics
- Proclara Bioscience
- Arcturus Therapeutics
Highlights of The Familial Amyloid Polyneuropathy Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- FAP-I
- FAP-II
- FAP-III
- FAP-IV
- By Application:
- Hospitals and Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Familial Amyloid Polyneuropathy Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Familial amyloid polyneuropathy is a rare disorder that affects the nervous system. The cause is unknown, but it may be caused by mutations in a gene called FAP. Symptoms include muscle weakness, difficulty walking, and problems with vision and hearing. There is no cure for familial amyloid polyneuropathy, but treatments can help improve symptoms.
Some of the key players operating in the familial amyloid polyneuropathy market are Pfizer, GSK, Ionis, Alnylam, Corino Therapeutics, Proclara Bioscience, Arcturus Therapeutics.
The familial amyloid polyneuropathy market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Familial Amyloid Polyneuropathy Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Familial Amyloid Polyneuropathy Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Familial Amyloid Polyneuropathy Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Familial Amyloid Polyneuropathy Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Familial Amyloid Polyneuropathy Market Size & Forecast, 2018-2028
4.5.1 Familial Amyloid Polyneuropathy Market Size and Y-o-Y Growth
4.5.2 Familial Amyloid Polyneuropathy Market Absolute $ Opportunity
Chapter 5 Global Familial Amyloid Polyneuropathy Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Familial Amyloid Polyneuropathy Market Size Forecast by Type
5.2.1 FAP-I
5.2.2 FAP-II
5.2.3 FAP-III
5.2.4 FAP-IV
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Familial Amyloid Polyneuropathy Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Familial Amyloid Polyneuropathy Market Size Forecast by Applications
6.2.1 Hospitals and Clinics
6.2.2 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Familial Amyloid Polyneuropathy Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Familial Amyloid Polyneuropathy Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Familial Amyloid Polyneuropathy Analysis and Forecast
9.1 Introduction
9.2 North America Familial Amyloid Polyneuropathy Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Familial Amyloid Polyneuropathy Market Size Forecast by Type
9.6.1 FAP-I
9.6.2 FAP-II
9.6.3 FAP-III
9.6.4 FAP-IV
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Familial Amyloid Polyneuropathy Market Size Forecast by Applications
9.10.1 Hospitals and Clinics
9.10.2 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Familial Amyloid Polyneuropathy Analysis and Forecast
10.1 Introduction
10.2 Europe Familial Amyloid Polyneuropathy Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Familial Amyloid Polyneuropathy Market Size Forecast by Type
10.6.1 FAP-I
10.6.2 FAP-II
10.6.3 FAP-III
10.6.4 FAP-IV
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Familial Amyloid Polyneuropathy Market Size Forecast by Applications
10.10.1 Hospitals and Clinics
10.10.2 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Familial Amyloid Polyneuropathy Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Familial Amyloid Polyneuropathy Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Familial Amyloid Polyneuropathy Market Size Forecast by Type
11.6.1 FAP-I
11.6.2 FAP-II
11.6.3 FAP-III
11.6.4 FAP-IV
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Familial Amyloid Polyneuropathy Market Size Forecast by Applications
11.10.1 Hospitals and Clinics
11.10.2 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Familial Amyloid Polyneuropathy Analysis and Forecast
12.1 Introduction
12.2 Latin America Familial Amyloid Polyneuropathy Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Familial Amyloid Polyneuropathy Market Size Forecast by Type
12.6.1 FAP-I
12.6.2 FAP-II
12.6.3 FAP-III
12.6.4 FAP-IV
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Familial Amyloid Polyneuropathy Market Size Forecast by Applications
12.10.1 Hospitals and Clinics
12.10.2 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Familial Amyloid Polyneuropathy Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Familial Amyloid Polyneuropathy Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Familial Amyloid Polyneuropathy Market Size Forecast by Type
13.6.1 FAP-I
13.6.2 FAP-II
13.6.3 FAP-III
13.6.4 FAP-IV
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Familial Amyloid Polyneuropathy Market Size Forecast by Applications
13.10.1 Hospitals and Clinics
13.10.2 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Familial Amyloid Polyneuropathy Market: Competitive Dashboard
14.2 Global Familial Amyloid Polyneuropathy Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 GSK
14.3.3 Ionis
14.3.4 Alnylam
14.3.5 Corino Therapeutics
14.3.6 Proclara Bioscience
14.3.7 Arcturus Therapeutics
